TOKYO/SINGAPORE, Sept 16 (Reuters) – Several Asian nations are quickly ramping up vaccination campaigns from shaky starts to combat growing COVID-19 infections, as supply shipments roll in and people overcome hesitancy in hopes of easing curbs and freeing up travel.
Japan and South Korea have passed the United States in terms of those who have received at least one dose and are fast catching up with the second.
And Australia, which is targeting high vaccination rates in its drive to escape lockdowns and re-open borders, has given 56% of people at least one shot as infections peak.
“That 70% double dose and 80% double dose mark is within plain sight,” Prime Minister Scott Morrison told media on Thursday in the capital, Canberra. “Keep going, Australia.”
While each country’s inoculation strategies differ, Asia’s momentum reflects pent-up demand for the shots as a means to ease lockdowns, said Paul Griffin, an infectious disease expert at the University of Queensland in northeast Australia.
Australia is giving priority supplies to its largest cities, which are in lockdown to contain a third wave of infections fuelled by the Delta variant. It expects to have enough to complete vaccinations of those older than 12 by mid-October. read more
Japan has overcome initial logistics hurdles to give about a million shots a day since mid-June, as urgency has grown after Delta unleashed an unprecedented wave of infections and serious cases in August.
“That obviously accelerated the vaccination motivation, particularly in young and middle-age groups,” said Takahiro Kinoshita, a physician and official of vaccine information group Cov-Navi.
Japan’s vaccination rate reflected a push to “return to a normal way of life,” Prime Minister Yoshihide Suga, who will step down this month after a one-year tenure marred by an unpopular COVID-19 response, said on Thursday. read more
Vaccine take-up was also boosted by consistent public messaging to counter health scares that have doomed similar previous drives, said Fumie Sakamoto, an infection control manager at St. Luke’s International Hospital in Tokyo.
CARROT AND STICK
Still, experts agree that vaccinations will plateau everywhere.
For instance, the United States and Britain, which had raced ahead to vaccinate millions of people a couple of months ago, are now seeing stagnating inoculation rates as large swathes of their populations reject the shots.
To counter the slowdown and a groundswell of anti-vaccine sentiment, U.S. President Joe Biden announced new mandates this week.
“I think they don’t have that same incentive that perhaps we do (in Australia), where we relied on very harsh restrictions to keep people safe … and are being told our only ticket to freedom is to have high levels of vaccination,” said Griffin.
China, where more than 70% of the population have received both doses, said this month that it was difficult to expand its vaccination drive but did not say where the roadblocks were. read more
In wealthy Singapore, the most inoculated nation in Asia with more than 80% people fully vaccinated, is turning its focus to booster doses as infections spike.
While there are some holdouts, especially among the elderly and those worried about side effects from the new mRNA vaccines, people have a high level of trust in the government, which helps with compliance.
“If the carrot is we’re going to ease restrictions if we get the vaccination rate high enough, then that will sway some people, it still won’t sway the completely recalcitrant,” said infectious diseases expert Dale Fisher, of the city state’s National University Hospital.
Singapore has tied its reopening to vaccination rate milestones and set limits on unvaccinated people dining at restaurants. read more
South Korea, which struggled to get vaccine supplies initially, has supercharged its campaign, thanks to increased shipments.
It is likely to reach more than 70% of its population with a first dose before this week, an official said on Thursday.
India, with the world’s second-highest tally of infections, has given 42% of its population of nearly 1.4 billion at least one dose, after months of production shortages and high demand.
Reporting by Rocky Swift in Tokyo and Aradhana Aravindan in Singapore; Additional reporting by John Mair and Hyonhee Shin in Seoul; Writing by Sayantani Ghosh; Editing by Miyoung Kim and Clarence Fernandez
Our Standards: The Thomson Reuters Trust Principles.